Core functions and those funded by fiscal year 2018 user fees are continuing, and 59% of the agency’s staffers are being retained.
Research suggests that working with a single contract partner can reduce development time and improve economics.
Despite the challenges and high cost of development, vaccine innovation is at an all-time high, as new approaches aim to improve global access.